The pharmaceutical landscape of the 2020s has been defined by the meteoric rise of GLP-1 receptor agonists. Drugs such as…
Read More
US Government Assumes Full Cost of Weight Loss Drugs for Medicare Beneficiaries Through Extended GLP-1 Bridge Program Amidst Insurer Hesitation
The Centers for Medicare & Medicaid Services (CMS) has announced a significant extension of its Medicare GLP-1 Bridge program, shifting…
Read More
The Alarming Rise of Unregulated Weight Loss Medications in the UK: A Public Health Crisis in the Making
British people are increasingly turning to potentially unregulated weight loss medications as drug prices climb and waits for prescriptions lengthen.…
Read More
Novo Nordisk’s triple agonist UBT251 delivered up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk, a global leader in diabetes and obesity care, has announced promising results from a Phase 2 trial of…
Read More
Lilly’s triple agonist achieves 16.8% weight loss in phase 3 trial.
Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read More
Salk Institute Researchers Identify BCL6 Protein as Critical Factor in Preventing Muscle Loss During Weight Loss and Aging
The rise of glucagon-like peptide-1 (GLP-1) receptor agonists has fundamentally altered the landscape of metabolic medicine in the United States.…
Read More
Genetic Variants Influence Weight Loss and Side Effect Efficacy of GLP-1 Drugs
A large-scale study analyzing the genetic data of 23andMe customers has identified specific variants in two genes that significantly influence…
Read More
Novo Nordisk’s new weight loss treatment inferior to Lilly’s tirzepatide
A Deep Dive into the Trial Results CagriSema, a novel combination therapy comprising cagrilintide and semaglutide, delivered an average weight…
Read More
Novo Nordisk’s triple agonist delivers up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk has announced significant positive results from a Phase 2 trial of its experimental triple agonist, UBT251, reporting a…
Read More
Lilly’s triple agonist achieves 16.8% weight loss in phase 3 trial
Eli Lilly’s investigational drug, retatrutide, a pioneering first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, has delivered extraordinary results…
Read More
